Search

Your search keyword '"Wang, Baoen"' showing total 2 results
Start Over Author "Wang, Baoen" Topic hepatitis b
2 results on '"Wang, Baoen"'

1. Economic analysis of recombinant interferon alpha 2b in the treatment of chronic hepatitis B and C

Author

Yao Guangbi and Wang Baoen

Subjects
medicine.medical_specialty, Cirrhosis, business.industry, Gastroenterology, Hepatitis C, Disease, Cost-effectiveness analysis, Hepatitis B, medicine.disease, Quality of life, Internal medicine, Hepatocellular carcinoma, Immunology, Cohort, medicine, business
Abstract

OBJECTIVE: To evaluate the long-term economic impact and benefits of interferon α 2b (IFNα 2b) treatment in patients with chronic hepatitis B and C. METHODS: Data from 6500 patients with chronic hepatitis B and C from 12 teaching hospitals in different areas of China were collected and analyzed. Cohorts of these patients with either chronic hepatitis B (2198 cases) or chronic hepatitis C (756 cases) that were treated with IFNα 2b were compared with a non-IFN- treated cohort (B, 2642 cases; C, 904 cases). Data from MEDLINE and Chinese Bio-Medical Database (CBMD) searches regarding the natural course of the disease, progression, efficacy and cost of IFN therapy were also included. Using a decision analysis software program, Markov computer simulation was used to estimate the progression of the disease and perform economic analyses. RESULTS: The 30-year disease progression to compensated and uncompensated cirrhosis and hepatocellular carcinoma in both chronic hepatitis B and C in the IFN-treated cohort was significantly decreased in comparison with the non-IFN-treated cohort. The results suggest that IFN treatment could increase life expectancy by 5.32 years in chronic hepatitis B and 4.06 years in chronic hepatitis C. In the IFN-treated group, life expectancy would increase by 5.41 and 4.27 quality-adjusted life-years (QALY), respectively. The cost to increase life expectancy by 1 QALY could be reduced by 5180 or 9066 yuan RMB in chronic hepatitis B or C patients treated with IFNα 2b, respectively. Over a 30-year period, the total direct medical costs would be reduced by 42 820 and 65 440 yuan RMB in chronic hepatitis B and C patients treated with IFNα 2b, respectively. CONCLUSION: Interferon α 2b therapy can prolong life expectancy, improve quality of life and lower the medical costs for patients with chronic hepatitis B and C.

Published
2000

2. Randomized clinical trial with two doses (100 and 40 ml) of Stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B

Author

Zhang, Lingxia and Wang, Baoen

Subjects
*GLYCYRRHIZA, *INTRAVENOUS therapy, *HEPATITIS B
Abstract

Stronger Neo-Minophagen C (SNMC) is an intravenous drug with glycyrrhizin as the principal ingredient. The efficacy and safety of SNMC at two doses were evaluated on 194 patients with chronic hepatitis B in nine hospitals in China. They all had serum levels of alanine aminotransferase (ALT) exceeding twice the upper limit of normal (>80 IU/l). SNMC daily 100 and 40 ml were given for 4 weeks to the patients randomized into Group A (N=99) and Group B (N=95), respectively. Thereafter, all patients received oral glycyrrhizin (GLYCYRON Tab) 9 tablets a day for an additional 4 weeks. Primary end-point was ALT<1.5 times the upper limit of normal (60 IU/l) at completion of the 8-week therapy, and it was achieved by 73 patients (74%) in Group A and 74 (79%) patients in Group B; normalization of ALT levels (<40 IU/l) was accomplished in 58 (58%) and 54 (57%) patients in Groups A and B, respectively. SNMC was withdrawn in four (2%) patients due to mild and reversible side effects. Based on these results, SNMC is safe and efficacious in lowering or normalizing ALT levels in patients with chronic hepatitis B in China, and an induction dose of 40 ml daily is efficient in achieving maximal effects. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results